Skip to main content
SpringerLink
Log in

Chemotherapy of Advanced Soft Tissue Sarcomas

  • Chapter
Recent Concepts in Sarcoma Treatment

Part of the book series: Developments in Oncology ((DION,volume 55))

Abstract

Doxorubicin (Adriamycin) and ifosfamide are the most active single agents in soft tissue sarcoma, with response rates of 15–35% in various trials. Dacarbazine (DTIC), frequently used in combinations, has a response rate as a single agent of 16%.

Both published randomized studies of doxorubicin with or without DTIC observed an increased response rate for the combination. All three randomized trials of doxorubicin based regimens with and without cyclophosphamide have failed to detect an advantage for the addition of cyclophosphamide. Thus, the most active standard combination for soft tissue sarcomas is doxorubicin and DTIC. A randomized trial of 5 gm/m2 of ifosfamide versus 1.5 gm/m2 of cyclophosphamide noted a higher response rate for ifosfamide with less myelo-suppression. A randomized study of doxorubicin and DTIC with and without ifosfamide is currently underway.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Klein HO, Wickramanayake PD, Dias P, Coerper CL, et al.: High-dose ifosfamide and mesna as continuous infusion over five days — a phase I/II trial. Cancer Treat Rev 10(Suppl.A):167–173, 1983.

    Article  PubMed  Google Scholar 

  2. Czownicki Z, Utracka-Hatka B: Clinical studies with uromitexan — an antidote against urotoxicity of holoxan. Preliminary results. Nowotwory 30:377–383, 1980.

    Google Scholar 

  3. Czownicki A, Utracka-Hutka B: Contribution to the treatment of malignant tumors with ifosfamide. In Burkert H, Voight HC, eds. Proc Intl Holoxan Symposium. Dusseldorf, W. Germany, Asta-Werke AG. pp.109–111, 1987.

    Google Scholar 

  4. Scheulen M, Niederle N, Seeber S: Results of a clinical phase II study on the use of ifosfamide in refractory malignant diseases. Comparison of the uroprotective effect of uromitexan and forced diuresis with alkalization of the urine. New Experience with the Oxazaphos-phorines with Special Reference to the Uroprotector Uromitexan, H. Burkert, Bielefeld, and GA Nagel, Gottingen, eds., pp.40, 1980.

    Google Scholar 

  5. Magrath IT, Sandlund JT, Rayner A, et al.: Treatment of recurrent sarcomas with ifosfamide (IF). ASCO. 4:136, 1985.

    Google Scholar 

  6. Bierbaum W, BHremer K, Firusian N, High M, et al.: Chemotherapeutische Behandlungsmoglichkeiten Bei Forgeschrittenen Sarkomen. Dtsch Med Wochenschr 106: 1181–1185, 1981.

    Article  PubMed  CAS  Google Scholar 

  7. Antman K, Montella D, et al.: Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep (in press).

    Google Scholar 

  8. Stuart-Harris R, Harper PG, Kaye SB, Wiltshaw E: High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 10(Suppl.A): 163–164, 1983.

    Article  PubMed  Google Scholar 

  9. Pratt C, Horowitz M, Meyer W, et al.: Phase II trial of ifosfamide (IFOS) with Mesna in patients with pediatric malignant solid tumors. ASCO 4:234, 1985.

    Google Scholar 

  10. Wellens W, Mussgnug G, Havets L, et al.: The combination ifosfamide/VP 16–213 in therapy of small cell bronchogenic carcinoma and other malignant tumors. In Burkert H, Nagel G, eds. Beitrage zur Onkologie, Vol 5, Basel and Munchen. Karger, pp. 81–87, 1980.

    Google Scholar 

  11. Wellens W, Donhuijsen-Ant R, Habets L, et al.: Therapie progredienter Sarkome mit Etososid und Ifosfamide. Etoposide Symposium, Aktuelle Onkologie, Zuckschwerdt Munchen. 4:159–164, 1981.

    Google Scholar 

  12. de Kraker J, Voute PA: Ifosfamide and vincristine in pediatric tumors. A phase II study. Eur Pediatr Haematol Oncol 1:47–50, 1984.

    Article  Google Scholar 

  13. Bramwell V, Mouridsen H, Santoro G, et al.: Cyclophosphamide (DP) versus ifosfamide (IF): A randomized phase II trial in adult soft tissue sarcoma (STS). Preliminary report of EORTC Soft Tissue and Bone Sarcomas Group. ASCO 4:143, 1985.

    Google Scholar 

  14. Blum RH: An overview of studies in adriamycin (NSC-123127) in the United States. Cancer Chemother Rep 6:247–251, 1975.

    Google Scholar 

  15. O’Bryan RM, Luce JK, Talley RW, et al.: Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1–8, 1973.

    Article  PubMed  Google Scholar 

  16. Creagan ET, Hahn RG, Ahmann DL, et al.: A clinical trial, adriamycin (NSC-123127) in advanced sarcomas. Oncology 34:90–91, 1977.

    Article  PubMed  CAS  Google Scholar 

  17. Schoenfeld D, Rosenbaum C, Horton J, et al.: A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide for advanced sarcoma. Cancer 50:27 57–2762, 1982.

    Google Scholar 

  18. Borden EC, Amato D, Enterline HT, Lerner H, Carbone PP: Randomized comparison of adriamycin regimens for treatment of metastatic soft tissue sarcomas. Proc ASCO 1983:231(C902).

    Google Scholar 

  19. Cruz AB Jr, Thames EA Jr, Aust JB, et al.: Combination chemotherapy for soft tissue sarcomas: A phase III study. J Surg Oncol 11:313–323, 1979.

    Article  PubMed  Google Scholar 

  20. O’Bryan RM, Baker LH, Gottlieb JE, et al.: Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940–1948, 1977.

    Article  PubMed  Google Scholar 

  21. Legha S, Benjamin RS, Mackay B, et al.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 96:133–139, 1982.

    PubMed  CAS  Google Scholar 

  22. Golbey R, Li MC, Kaufman RF: Actinomycin in the treatment of soft part sarcomas. James Ewing Society Scientific Program (abstr.), 1968.

    Google Scholar 

  23. Rosenberg SA, Suit HD, Baker LH: Sarcomas of Soft Tissue. In Cancer, Principals & Practice of Oncology, 2nd ed., Philadelphia, JB Lippincott, p.1243.

    Google Scholar 

  24. Andrews N, Wilson W: Phase II study of methotrexate (NSC 740) in solid tumors. Cancer Chemother Rep 51:471–474, 1967.

    Google Scholar 

  25. Subramanian S, Wiltshaw E: Chemotherapy of sarcoma — A comparison of three regimens. Lancet pp.683–686, 1978.

    Google Scholar 

  26. Rosen G, Caparros B, Nirenberg A, et al.: High dose methotrexate (HDMTX) with citrovorum factor rescue (CFR) in the treatment of radiation-induced sarcomas. Proc AACR 1983:194, 1981.

    Google Scholar 

  27. Frei E, Blum R, Pitman S, et al.: High dose methotrexate with leucovorin rescue: Rationale and spectrum of antitumor activity, Am J Med 68:370–375, 1979.

    Article  Google Scholar 

  28. Vaughn C, McKelvey E, Balcerzak S, et al.: High dose methotrexate with leucovorin rescue plus vincristine in advanced sarcoma: A Southwest Oncology Group Study. Cancer Treat Rep 68:409–410, 1984.

    PubMed  CAS  Google Scholar 

  29. Ambinder EP, Perloff M, Ohnuma T, et al.: High-dose methotrexate followed by citrovorum factor reversal in patients with advanced cancer. Cancer 43:1177–1182, 1979.

    Article  PubMed  CAS  Google Scholar 

  30. Karakousis CP, Rao U, Carlson M: High-dose methotrexate as secondary chemotherapy in metastatic soft-tissue sarcomas. Cancer 46:1345–2=1348, 1980.

    Article  PubMed  CAS  Google Scholar 

  31. Von Hoff DD, Rozencwieg M, Louie AC, et al: “Single”-agent activity of high-dose methotrexate therapy with citrovorum factor rescue. Cancer Treat Rep 62:233–235, 1978.

    Google Scholar 

  32. Isacoff WH, Eilber F, Tabbarah H, et al.: Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue. Cancer Treat Rep 62:1295–1304, 1978.

    PubMed  CAS  Google Scholar 

  33. Brarawell VHC, Brugarols A, Mouridsen HT, et al.: EORTC. Phase II study of cisplatinum CYVADIC-resistant soft tissue sarcoma. Eur J Cancer 15:1511–1513, 1979.

    Article  Google Scholar 

  34. Karakousis CP, Holterman OA, Holyoke ED: Cisdichloro-diammineplatinum (II) in metastatic soft tissue sarcomas. Cancer Treat Rep 63:2071–2075, 1979.

    PubMed  CAS  Google Scholar 

  35. Samson MK, Baker LH, Benhamin RS, et al.: Cis-dichloro-diammineplatinum (II) in advanced soft tissue and bony sarcomas. A Southwest Oncology Group Study. Cancer Treat Rep 63:2027–2028, 1979.

    PubMed  CAS  Google Scholar 

  36. Gershenson DM, Kavanagh JJ, Copeland LJ, et al.: Cis-platin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol (in press).

    Google Scholar 

  37. Bergsagel DE, Levin WC: A prelusive clinical trial of cyclophosphamide. Cancer Chemother Rep 8:120–134, 1960.

    PubMed  Google Scholar 

  38. Korst DR, Johnson D, Frenkel EP, et al.: Preliminary evaluation of the effect of cyclophosphamide on the course of human neoplasms. Cancer Chemother Rep 7:1–12, 1960.

    Google Scholar 

  39. Radice PA, Bunn PA Jr, Ihde DC: Therapeutic trials with VP-16 and VM26. Cancer Treat Rep 63:1231–1239, 1979.

    PubMed  CAS  Google Scholar 

  40. Bleyer WA, Chard R, Krivit W, et al.: Epipodophyllotoxin therapy of childhood neoplasia. A comparative phase II analysis of VM-26 and VP 16–213. Proc Am Assoc Cancer Res 19:373, 1978.

    Google Scholar 

  41. Amato DA, Borden EC, Shiraki M, et al.: Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma. Investigational New Drugs 3:397–401, 1985.

    Article  PubMed  CAS  Google Scholar 

  42. Selawry OS, Holland JF, Wolman IJ: Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep 52:497–499, 1968.

    PubMed  CAS  Google Scholar 

  43. Korbitz BC, Davis HL Jr, Ramirez G, et al.: Low doses of vincristine (NSC-67574) for malignant disease. Cancer Chemother Rep 53:249–254, 1969.

    PubMed  CAS  Google Scholar 

  44. Gold G, Hall T, Shnider B, et al.: A clinical study of 5-fluorouracil. Cancer Research 19:935–939, 1959.

    PubMed  CAS  Google Scholar 

  45. Bodey GP, et al.: Protected environment — prophylactic antibiotic program for malignant sarcoma: randomized trial during remission induction chemotherapy. Cancer 47:2422–2429, 1981.

    Article  PubMed  CAS  Google Scholar 

  46. Pinedo HM, Bramwell VHC, et al.: CYVADIC in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 53:1825–1832, 1984.

    Article  PubMed  CAS  Google Scholar 

  47. Omura GA, et al.: A randomized study of adriamycin with and without dimethyl trazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626–632, 1983.

    Article  PubMed  CAS  Google Scholar 

  48. Lerner H, Amato D, Stevens C, et al.: Leiomyosarcoma: the Eastern Cooperative Oncology Group experience with 222 patients. Proc Am Assoc Cancer Res 24:142(C-561), 1983.

    Google Scholar 

  49. Baker, LH: Personal communication.

    Google Scholar 

  50. Muss HB, Bundy B, DeSaia P, et al.: Treatment of recurrent or advanced uterine sarcoma — a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 55:1648–1653, 1985.

    Article  PubMed  CAS  Google Scholar 

  51. Benjamin RS, Gottlieb JA, Baker LH, et al.: CYVADIC vs CYVADACT- a randomized trial of cyclophosphamide (CY), vincristine (V), and adriamycin (A) plus either dacarba-zine (DIC) or actinomycin-D (DACT) in metastatic sarcomas. Proc Am Assoc Cancer Res, Am Soc Clin Oncol 17:256, 1976.

    Google Scholar 

  52. Baker L, Green S, Ryan J, et al.: SWOG 8024: Combined modality therapy for disseminated soft tissue sarcoma, Phase III. Proceeding of ASCO 6:138 (abstr. no.542), 1987.

    Google Scholar 

  53. Gottlieb JA, Baker LH, et al.: Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep. 6:271–282, 1975.

    Google Scholar 

  54. Blum R, Corson J, et al.: Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD). Cancer 46:1722–1726, 1980.

    Article  PubMed  CAS  Google Scholar 

  55. Subramanian S, Wiltshaw E: Chemotherapy of sarcoma. A Comparison of three regimens. The Lancet pp.683, 1978.

    Google Scholar 

  56. Yap BS, Sinkovics JG, Benjamim RS, et al.: Survival and relapse patterns of complete responders in adults with advanced soft tissue sarcomas (ASTS). Proc Am Assoc Cancer Res and ASCO 20:352, 1979.

    Google Scholar 

  57. Otten J, Flamant F, Rodary C, et al: Effectiveness of combination of ifosfamide, vincristine and actinomycine D in inducing remission in rhabdomyosarcoma in children. For the RMS group of the International Society of Pediatric Oncology (SIOP). ASCO 4:236, 1985.

    Google Scholar 

  58. Schutte J, Dombernowsky P, Santoro A, et al.: Adriamycin (A) and ifosfamide (I), a new effective combination in advanced soft tissue sarcoma? preliminary report of a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Proc of ASCO 5:145, 1986.

    Google Scholar 

  59. Elias AD, Antman K, Ryan L: Doxorubicin (DOX), ifosfa-mide (IFF), and DTIC with mesna uroprotection for advanced untreated sarcoma. Proc of ASCO, 1987.

    Google Scholar 

  60. Elias A, Antman K: Doxorubicin, ifosfamide, and dacarba-zine (AID) with mesna uroprotection for advanced untreated sarcoma: a Phase I study. Cancer Treat Rep, 70:827–833, 1986.

    PubMed  CAS  Google Scholar 

  61. Gottlieb JA, Maker LH, Quagliana JM, et al.: Chemotherapy of sarcomas with a combination of adriamycin and diemthyltrazenoimidazolecarboxamide. Cancer 30:1632–1638, 1972.

    Article  PubMed  CAS  Google Scholar 

  62. Gottlieb JA, Baker LH, Burgess MA, et al.: Sarcoma Chemotherapy. In Cancer Chemotherapy Fundamental Concepts and Recent Advances. 19th Annual Clinical Conference in Cancer, 1974, M.D. Anderson Hospital, Year Book Medical Publishers, 1975.

    Google Scholar 

  63. Creagan ET, Hahn JRG, Ahmann DL, et al.: A comparative clinical trial evaluating the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomas. Cancer Treat Rep 60:1385–1386, 1976.

    PubMed  CAS  Google Scholar 

  64. Yap B, Baker LH, Sinkovics JG, et al.: Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64:93–98, 1980.

    PubMed  CAS  Google Scholar 

  65. Pinedo HM, Vendrik CPJ, Bramwell VHC, et al.: Re-evaluation of the CYVADIC regimen for metastatic soft tissue sarcoma. Proc AACR and ASCO (abstr.) C-228, 1979.

    Google Scholar 

  66. Shiv MH, Magill GB, Hopfan S: Recent Trends in Treatment of Soft Tissue Sarcomas-Appendix A. In Hajdu SI (ed.): Pathology of Soft Tumors, Philadelphia, Lea & Febiger, pp.537–542. 1979.

    Google Scholar 

  67. Lowenbraun S, Moffitt JS, Smalley R, et al.: Combination chemotherapy with adriamycin, cyclophosphamide and methotrexate in metastatic sarcomas. ASCO (abstr.) 18:289, 1977.

    Google Scholar 

  68. Rivkin SE, Gottlieb JA, Thigpen T, et al: Methyl CCNU and adriamycin for patients with metastatic sarcomas. A Southwest Oncology Group Study. Cancer 46:446–451, 1980.

    Article  PubMed  CAS  Google Scholar 

  69. Chang P, Wiernik PH: Combination chemotherapy with adriamycin and streptozotocin. Clin Pharmacol Ther 20:605–610, 1976.

    PubMed  CAS  Google Scholar 

  70. Kaufman JH, Catane R, Douglass HO: Combined adriamycin, vincristine, and methotrexate. NY State J Med 742–743, 1977.

    Google Scholar 

  71. Jacobs EM: Combination chemotherapy of metastatic testicular germinal cell tumors and soft part sarcomas. Cancer 25:324–332, 1970.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medicine, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115, USA

    Karen H. Antman M.D.

Authors
  1. Karen H. Antman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Orthopedic Surgery, Wayne State University School of Medicine, Detroit, Michigan, 48201, USA

    James R. Ryan MD (Associate Professor, Chief Orthopedic Oncology) (Associate Professor, Chief Orthopedic Oncology)

  2. Department of Internal Medicine, Division of Hematology-Oncology, Wayne State University School of Medicine, Detroit, Michigan, 48201, USA

    Laurence O. Baker D.O. (Professor, Director) (Professor, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Kluwer Academic Publishers

About this chapter

Cite this chapter

Antman, K.H. (1988). Chemotherapy of Advanced Soft Tissue Sarcomas. In: Ryan, J.R., Baker, L.O. (eds) Recent Concepts in Sarcoma Treatment. Developments in Oncology, vol 55. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-2691-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-2691-2_27

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-7714-9

  • Online ISBN: 978-94-009-2691-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation